This study will describe and compare the rates of asthma exacerbations observed between 12-month pre-switch and 12-month post-switch periods among participants switching to AIRSUPRA. Other outcome measures included in this study are asthma-related oral corticosteroid (OCS) use, and asthma exacerbation-related healthcare resource utilization (HCRU), healthcare cost, and patient reported outcomes (PROs).
Search Tufts Medicine
A team led by Tufts Medical Center neurosurgeon Dr. Ron Riesenburger, Interim Chair of Neurosurgery, Co-chief of Spinal Surgery and Director of the Spine Center, corrected Peter Bradford severe spinal condition and helped him regain his mobility.
The primary goal of this study is to improve our understanding of changes in skeletal muscle mass in the arms and the legs during a hospitalization for advanced HF. We plan to measure muscle thickness with an ultrasound machine in two locations on the body (the outer thigh and the upper arm muscle, of the dominant side) from the time a patient is first admitted to the ICU with HF as well as before and after any surgical HF therapies.
This is a Phase 2/3 study designed to evaluate the efficacy and safety of BIIB059 for the treatment of participants with active SCLE and/or CCLE with or without systemic manifestations and refractory and/or intolerant to antimalarial therapy.
This will be a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PLS240 in eligible participants with ESKD and SHPT.